Advertisement

Effect of Fluconazole and Itraconazole on the Pharmacokinetics of Erdafitinib in Healthy Adults: A Randomized, Open-Label, Drug–Drug Interaction Study

  • Italo PoggesiEmail author
  • Lilian Y. Li
  • James Jiao
  • Peter Hellemans
  • Freya Rasschaert
  • Loeckie de Zwart
  • Jan Snoeys
  • Marc De Meulder
  • Rao N. V. S. Mamidi
  • Daniele Ouellet
Original Research Article
  • 23 Downloads

Abstract

Background and Objectives

Erdafitinib, an oral selective pan-fibroblast growth factor receptor (FGFR) kinase inhibitor, is primarily metabolized by cytochrome P450 (CYP) 2C9 and 3A4. The aim of this phase 1 study was to assess the pharmacokinetics and safety of erdafitinib in healthy participants when coadministered with fluconazole (moderate CYP2C9 and CYP3A inhibitor), and itraconazole (a strong CYP3A4 and P-glycoprotein inhibitor). The effect of CYP2C9 genotype variants (*1/*1, *1/*2, *1/*3) on the pharmacokinetics of erdafitinib was also investigated.

Methods

In this open-label, parallel-group, single-center study, eligible healthy adults were randomized by CYP2C9 genotype to receive Treatment A (single oral dose of erdafitinib 4 mg) on day 1, Treatment B (fluconazole 400 mg/day orally) on days 1–11, or Treatment C (itraconazole 200 mg/day orally) on days 1–11. Healthy adults randomized to Treatment B and C received a single oral 4-mg dose of erdafitinib on day 5. The pharmacokinetic parameters, including mean maximum plasma concentration (Cmax), area under the curve (AUC) from time 0 to 168 h (AUC168h), AUC from time 0 to the last quantifiable concentration (AUClast), and AUC from time 0 to infinity (AUC) were calculated from individual plasma concentration–time data using standard non-compartmental methods.

Results

Coadministration of erdafitinib with fluconazole increased Cmax of erdafitinib by approximately 21%, AUC168h by 38%, AUClast by 49%, and AUC by 48% while coadministration with itraconazole resulted in no change in erdafitinib Cmax and increased AUC168h by 20%, AUClast by 33% and AUC by 34%. Erdafitinib exposure was comparable between participants with CYP2C9 *1/*2 or *1/*3 and with wild-type CYP2C9 genotype. The ratio of total amount of erdafitinib excreted in the urine (inhibited to non-inhibited) was 1.09, the ratio of total amount of excreted metabolite M6 was 1.21, and the ratio of the metabolite to parent ratio in the urine was 1.11, when coadministration of erdafitinib with itraconazole was compared with single-dose erdafitinib. Treatment-emergent adverse events (TEAEs) were generally Grade 1 or 2 in severity; the most commonly reported TEAE was headache. No safety concerns were identified with single-dose erdafitinib when administered alone and in combination with fluconazole or itraconazole in healthy adults.

Conclusion

Coadministration of fluconazole or itraconazole or other moderate/strong CYP2C9 or CYP3A4 inhibitors may increase exposure to erdafitinib in healthy adults and thus may warrant erdafitinib dose reduction or use of alternative concomitant medications with no or minimal CYP2C9 or CYP3A4 inhibition potential.

Trial Registration

ClinicalTrials.gov identifier number: NCT03135106.

Notes

Acknowledgements

Investigational compound erdafitinib (JNJ-42756493) was discovered in collaboration with Astex Pharmaceuticals. This study was supported by Janssen Research & Development, LLC. The authors thank all the volunteers for their participation in this study and acknowledge the collaboration and commitment of all investigators and their staff. The authors also thank Jan de Jong (Janssen Research & Development, LLC) for his contribution in the study design, data analysis and interpretation, and Yvonne Lau for review of the manuscript. Writing assistance was provided by Ramji Narayanan, M Pharm, ISMPP CMPP™ (SIRO Clinpharm Pvt. Ltd.) funded by Janssen Global Services and additional editorial support for this manuscript was provided by Harry Ma, PhD (Janssen Global Services, LLC).

Author contribution

First and second authors have equally contributed to this manuscript. All authors had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. All authors meet ICMJE criteria and all those who fulfilled those criteria are listed as authors. All authors provided direction and comments on the manuscript, made the final decision about where to publish these data, and approved submission to this journal.

Compliance with Ethical Standards

Funding

Janssen Research & Development LLC.

Conflict of interest

All authors were employees of Janssen Research & Development, LLC.

Ethical approval

The study protocol and amendments were approved by an Independent Ethics Committee. The study was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki and consistent with the International Conference on Harmonization, Good Clinical Practice guidelines, and applicable regulatory requirements.

Informed consent

Written informed consent was obtained from all individuals to participate in the study.

Supplementary material

13318_2019_581_MOESM1_ESM.pdf (110 kb)
Supplementary material 1 (PDF 109 kb)

References

  1. 1.
    Perera TPS, Jovcheva E, Mevellec L, Vialard J, De Lange D, Verhulst T, Paulussen C, Van De Ven K, King P, Freyne E, Rees DC, Squires M, Saxty G, Page M, Murray CW, Gilissen R, Ward G, Thompson NT, Newell DR, Cheng N, Xie L, Yang J, Platero SJ, Karkera JD, Moy C, Angibaud P, Laquerre S, Lorenzi MV. Discovery and pharmacological characterization of JNJ-42756493 (erdafitinib), a functionally selective small-molecule FGFR family inhibitor. Mol Cancer Ther. 2017;16(6):1010–20.CrossRefGoogle Scholar
  2. 2.
    Loriot Y, Necchi A, Park SH, García-Donas J, Huddart RA, Burgess EF, Fleming MT, Rezazadeh A, Mellado B, Varlamov S, Joshi M, Duran I, Ohagan A, Avadhani AN, Zhong B, Stuyckens K, Dosne A-G, Siefker-Radtke AO. Erdafitinib (ERDA; JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRa): phase 2 continuous versus intermittent dosing. J Clin Oncol. 2018;36(suppl 6S):abstr 411.CrossRefGoogle Scholar
  3. 3.
    Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, Fleming M, Rezazadeh A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y, Zhong B, Stuyckens K, Santiago-Walker A, De Porre P, O'Hagan A, Avadhani A, Siefker-Radtke AO; BLC200 Study Group. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019;381(4):338–48.CrossRefGoogle Scholar
  4. 4.
    BALVERSA (erdafitinib) [prescribing information] Janssen Pharmaceuticals; 2019.Google Scholar
  5. 5.
    US FDA. Guidance for Industry Drug interaction studies—study design, data analysis, implications for dosing, and labeling recommendation, 2012. Draft guidance. 2013. Accessed 30 Aug 2017.Google Scholar
  6. 6.
    European Medicines Agency. Guideline on the investigation of drug interactions. 2012. http://www.ema.europa.eu/docs/en_GB/document_library/Scientificguideline/2012/07/WC500129606.pdf. Accessed 14 Dec 2018.
  7. 7.
    Vogl S, Lutz RW, Schonfelder G, Lutz WK. CYP2C9 genotype vs. metabolic phenotype for individual drug dosing–a correlation analysis using flurbiprofen as probe drug. PLoS One. 2015;10(3):e0120403.CrossRefGoogle Scholar
  8. 8.
    Daly AK, Rettie AE, Fowler DM, Miners JO. Pharmacogenomics of CYP2C9: functional and clinical considerations. J Pers Med. 2017;8(1):E1.CrossRefGoogle Scholar
  9. 9.
    Isoherranen N, Lutz JD, Chung SP, Hachad H, Levy RH, Ragueneau-Majlessi I. Importance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro data. Chem Res Toxicol. 2012;25(11):2285–300.CrossRefGoogle Scholar
  10. 10.
    Huang Z, Ung T. Effect of alpha-1-acid glycoprotein binding on pharmacokinetics and pharmacodynamics. Curr Drug Metab. 2013;14(2):226–38.PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Italo Poggesi
    • 1
    Email author
  • Lilian Y. Li
    • 2
  • James Jiao
    • 3
  • Peter Hellemans
    • 4
  • Freya Rasschaert
    • 4
  • Loeckie de Zwart
    • 4
  • Jan Snoeys
    • 4
  • Marc De Meulder
    • 4
  • Rao N. V. S. Mamidi
    • 3
  • Daniele Ouellet
    • 2
  1. 1.Global Clinical PharmacologyQuantitative Sciences, Janssen-Cilag SpACologno MonzeseItaly
  2. 2.Janssen Research & DevelopmentSpringhouseUSA
  3. 3.Janssen Research & DevelopmentRaritanUSA
  4. 4.Janssen Research & DevelopmentBeerseBelgium

Personalised recommendations